75 /100
HIGH RISK
Score updated Jul 14, 2026

MDCX — Medicus Pharma Ltd. Dilution Risk Tracker

Track MDCX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track MDCX — Get alerts when the score changes →

As of July 14, 2026, Medicus Pharma Ltd. (MDCX) has a DilutionWatch DilutionScore of 75/100, rated HIGH dilution risk. Medicus Pharma Ltd. has a market capitalization of $21.47M, 56.66M shares outstanding, 10 institutional holders tracked. Key dilution vectors include shelf registration capacity of $8.04M, ATM program capacity of $15.00M, approximately 3 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
85
💰 Cash Runway
85
📊 Float Risk
5
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
59%
💰 Capital Raise 73%
• Low cash runway: 3 months remaining
• Active shelf registration ($8M, 37% of market cap)
🔄 Reverse Split 70%
• 50-day avg $0.36 below $1 exchange minimum
• Only 3 months cash — financial pressure
📉 Score Deterioration 10%
• Score in HIGH risk zone (75/100)
🔔 Track MDCX — Get forecast alerts →

💹 Market Data

Market Cap$21.47M
Shares Outstanding56.66M
Float50.14M
Cash$6.37M
Debt$2.34M
Short InterestN/A

🏛 Institutional Holdings

10 institutional holders · 3.93M shares
#1 Armistice Capital, LLC 1.81M shares
#2 Interchange Capital Partners, LLC 1.66M shares
#3 Private Advisor Group, LLC 175.5K shares
+ 7 more holders Sign up free to view →

📉 Short Interest

Short Interest1.05M
Days to Cover1.0
% of Float2.1%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2025
4 INSIDER TRANSACTION Jun 04, 2026
424B3 ATM Jun 04, 2026
4 INSIDER TRANSACTION Jun 04, 2026
Full SEC filing analysis available with free account

📰 Recent News

📋 What This Means for MDCX Shareholders

Medicus Pharma Ltd. (MDCX) has a DilutionScore of 75/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

The most significant dilution vector for MDCX is its shelf registration capacity of $8.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely. MDCX has an active ATM (at-the-market) program with $15.0M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event.

DilutionWatch tracks over 25 SEC filing types for MDCX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for MDCX alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding Shelf Registrations → How ATM Offerings Work →
Track MDCX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking MDCX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for MDCX
📊 MDCX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 MDCX Signal Convergence & Dark Pool Activity — StonkWhisper 📄 MDCX Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.